| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5879316 | The Journal of Pain | 2015 | 13 Pages |
Abstract
The S enantiomer of bupranolol, a β-receptor antagonist, shows greater antinociceptive efficacy and a superior preclinical safety profile and it should be considered as a unique β-adrenergic receptor compound to advance future clinical pain studies.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Loren J. Martin, Marjo H. Piltonen, Josee Gauthier, Marino Convertino, Erinn L. Acland, Nikolay V. Dokholyan, Jeffrey S. Mogil, Luda Diatchenko, William Maixner,